Search research articles
Contact Us
Filters
Showing results (81-90 of 115) with videos related to
Page
of 12
Sort By:
The Lancet. Oncology
|
January 5, 2025
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study
Toni K Choueiri, Jaime R Merchan, Robert Figlin, et al.
The Lancet. Oncology
|
October 21, 2015
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Robert J Motzer, Thomas E Hutson, Hilary Glen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
November 15, 2013
Models of care and NCCN guideline adherence in very-low-risk prostate cancer
Ayal A Aizer, Jonathan J Paly, Anthony L Zietman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2012
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer
Ayal A Aizer, Jonathan J Paly, Anthony L Zietman, et al.
The Oncologist
|
July 23, 2020
The Art of Oncology: COVID-19 Era
Kerry L Reynolds, Samuel J Klempner, Aparna Parikh, et al.
JAMA
|
June 8, 2006
Sunitinib in patients with metastatic renal cell carcinoma
Robert J Motzer, Brian I Rini, Ronald M Bukowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 7, 2005
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
Robert J Motzer, M Dror Michaelson, Bruce G Redman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 11, 2013
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer
M Dror Michaelson, Stephane Oudard, Yen-Chuan Ou, et al.
Cancer Immunology Research
|
February 14, 2018
Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
Dylan J Martini, Lana Hamieh, Rana R McKay, et al.
JCO Precision Oncology
|
February 16, 2022
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma
Bradley A McGregor, Wanling Xie, Elio Adib, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 115) with videos related to
Sort By:
Page
of 12
The Lancet. Oncology
|
January 5, 2025
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study
Toni K Choueiri, Jaime R Merchan, Robert Figlin, et al.
The Lancet. Oncology
|
October 21, 2015
Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
Robert J Motzer, Thomas E Hutson, Hilary Glen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
November 15, 2013
Models of care and NCCN guideline adherence in very-low-risk prostate cancer
Ayal A Aizer, Jonathan J Paly, Anthony L Zietman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 2, 2012
Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer
Ayal A Aizer, Jonathan J Paly, Anthony L Zietman, et al.
The Oncologist
|
July 23, 2020
The Art of Oncology: COVID-19 Era
Kerry L Reynolds, Samuel J Klempner, Aparna Parikh, et al.
JAMA
|
June 8, 2006
Sunitinib in patients with metastatic renal cell carcinoma
Robert J Motzer, Brian I Rini, Ronald M Bukowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 7, 2005
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
Robert J Motzer, M Dror Michaelson, Bruce G Redman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 11, 2013
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer
M Dror Michaelson, Stephane Oudard, Yen-Chuan Ou, et al.
Cancer Immunology Research
|
February 14, 2018
Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events
Dylan J Martini, Lana Hamieh, Rana R McKay, et al.
JCO Precision Oncology
|
February 16, 2022
Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma
Bradley A McGregor, Wanling Xie, Elio Adib, et al.
Page
of 12